<DOC>
	<DOCNO>NCT01115296</DOCNO>
	<brief_summary>Helicobacter pylorus colonises estimate 50 % world´s population ( Taylor &amp; Blaser , 1991 ; Go , 2002 ) . Despite clear clinical guideline treatment infection ( Malfertheiner et al . 2007 ) drive find alternative way control infection wider perspective without complication induction antibiotic resistance pathogen . L. reuteri widely study clinical trial show probiotic , health-promoting effect adult child ( Connolly 2004 ; Casas &amp; Dobrogosz , 2000 ) . L. reuteri show numerous study safe human consumption show colonise human gastrointestinal tract ( Wolf et al. , 1995 , Valeur et al. , 2004 ) . Studies use supplementation L. reuteri symptomatic non-symptomatic H. pylori-infected subject show clear reduction infection load 4 week use concomitant reduction symptom associate infection ( Imase et al . 2007 ; Francavilla et al . 2007 , unpublished data ) . Further , dietary supplementation L. reuteri period H. pylori eradication therapy also show reduce side effect therapy without affect degree eradication ( Lionetti et al. , 2007 ) . It also feasible , inhibitory action L. reuteri H. pylorus , pre-exposure L. reuteri may weaken H. pylorus make susceptible antibiotic attack eradication . However , early pilot study able demonstrate reduction gastric inflammation cause H. pylorus . This pilot study perform L. reuteri ATCC 55730 since find lack anti-inflammatory activity vitro screen . Recent selection natural , human L. reuteri strain identify specific strain strong anti-inflammatory property vitro ( Lin et al , 2007 submit 2007 ) . A combination strain , together early proven L. reuteri strain , expect lead reduction H. pylorus load well reduction gastric inflammation relate pathogen .</brief_summary>
	<brief_title>Control Helicobacter Pylori Infection Probiotics</brief_title>
	<detailed_description>INVESTIGATIONAL PLAN AND PROCEDURES Randomised , double-blind , placebo-controlled clinical trial . One hundred ( 100 ) subject , age 18-65 year recruit patient symptom refer consultation H. pylori infection naive treatment . HP infect patient randomly allocate two group , one receive L. reuteri receive identical placebo preparation . Baseline test : 1 . 13C-UBT 2 . Gastrointestinal symptom rating score ( GSRS ) 3 . Serological assessment H. pylori 4 . Measurement marker serum peptide related gastric inflammation . The subject ask take study product day 28 day . On Day 29 , subject return clinic repeat analysis : 1 . 13C-UBT 2 . Gastrointestinal symptom rating score ( GSRS ) 3 . Measurement marker serum peptide related gastric inflammation . 4 . Endoscopy collection 5 gastric biopsy sample ( 4 antrum 1 corpus ) . After analysis ( Day 29 ) , eradication treatment initiate . Patients receive lansoprazole ( 30 mg b.d . ) plus amoxycillin ( 1 gr b.d . ) 5 day follow lansoprazole ( 30 mg b.d . ) plus clarithromycin ( 250 b.d . ) tinidazole ( 500 b.d . ) next 5 day , recommend Maastricht III criterion ( Malfertheiner et al . ( 2007 ) . The study product administer throughout eradication treatment period 10 day . At end eradication therapy subject return clinic repeat analysis : 1 . Gastrointestinal symptom rating score ( GSRS ) 2 . Measurement marker serum peptide related gastric inflammation . At visit patient give GSRS questionnaire complete home 30 day visit . The complete GSRS shall give investigator final visit patient . The subject continue take study product 60 day completion eradication . After 60 day ( allow discrimination recrudescence re-infection ) , level eradication H. pylorus symptom score analyse 1 . 13C-UBT 2 . Gastrointestinal symptom rating score ( GSRS ) 3 . Measurement marker serum peptide related gastric inflammation . Concomitant treatment During period study ( eradication therapy ) , subject refrain ingestion kind probiotic bacterial preparation , antibiotic , H2-antagonists , PPIs NSAIDs . Study Product Dosage L. reuteri Progastria consist mixture two human strain L. reuteri , L. reuteri DSM 17938 L. reuteri ATCC PTA 6475 . L. reuteri DSM 17938 essentially strain L. reuteri ATCC 55730 , except lack plasmid carry antibiotic resistance trait tetracycline lincomycin . This strain extensively study human age . L. reuteri ATCC PTA 6475 new strain isolate breast milk nursing mother ( L. reuteri DSM 17938 ) . L. reuteri deliver dose 1x108 CFU strain L. reuteri give final dose L. reuteri 2x108 CFU . One dose take per day give dose L. reuteri 2x108 CFU/day . This dose L. reuteri show effective series condition earlier , include inhibition H. pylorus human , consider optimal dose .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<criteria>Subjects age 18 65 year Infection H. pylorus define ∆ &gt; 20 ppm UBT test Nonulcer dyspepsia No early eradication therapy H. pylori infection Written inform consent Stated availability throughout entire study period Mental ability understand willingness fulfil detail protocol . Duodenal gastric ulcer MALT lymphoma Gastric resection ( time ) First level relative gastric cancer patient Absence GI symptom Use NSAIDs , aspirin antiinflammatory drug within 1 week ( occasional use ) 3 week ( chronic use ) inclusion Use oral antibiotic and/or PPIs and/or H2antagonists 2 week prior ingestion study product Pregnancy Participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Helicobacter Pylori</keyword>
	<keyword>gastritis</keyword>
	<keyword>Probiotics</keyword>
	<keyword>Lactobacillus Reuteri</keyword>
</DOC>